Safety Issues Clinical Trial
Official title:
Safety and Tolerability of Soy Fiber in the Elderly: A Dose Escalation Study
Verified date | May 2023 |
Source | Pennington Biomedical Research Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a dose escalation trial in the elderly with obesity to determine the maximum tolerated dose of a novel dietary fiber from whole young soy pods (soy) delivered in foods.
Status | Completed |
Enrollment | 8 |
Est. completion date | April 14, 2022 |
Est. primary completion date | April 14, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 70 Years to 85 Years |
Eligibility | Inclusion Criteria: - Adult (70 - 85 years). - Body mass index between 30 and 40 kg/m2. - No evidence of diabetes (fasting blood sugar <126 mg/dL). - No evidence of dementia (MMSE score > 25). - No evidence of depression. (Geriatric Depression Scale-15 [GDS-15] < 6. - Are weight stable (< 3 kg weight change in the past three months). Exclusion Criteria: - Have type 1 or type 2 diabetes currently being treated by medication. - Report clinically significant gastrointestinal malabsorption syndromes such as chronic diarrhea, or celiac disease. - Are being treated with medications that have a significant effect on insulin resistance, obesity, and metabolic rate, or medications that significantly increase body weight such as antidepressants, second-generation antipsychotics, systemic glucocorticoids, and adrenergic blockers or stimulators (unless the dose and body weight have been stable for six months). - Have serum triglyceride concentrations > 400 mg/dl. - Clinically significant abnormal laboratory markers (as determined by the medical investigator). - Subjects with anticipated surgery during the study period. - Subjects with a reported history of substance abuse or alcoholism or significant psychiatric disorder that would interfere with the ability to complete the study. - Subjects who are current smokers or have smoked within the previous three months. Smoking is not permitted during the study. - Subjects who are unable to provide a baseline blood or fecal sample or if they have any condition that impedes testing of the study hypothesis or makes it unsafe to consume the food being tested in the study (determined by the investigative team). - Women on hormone replacement therapy unless weight has been stable over the last six months. |
Country | Name | City | State |
---|---|---|---|
United States | Pennington Biomedical Research Center | Baton Rouge | Louisiana |
Lead Sponsor | Collaborator |
---|---|
Pennington Biomedical Research Center | National Institute on Aging (NIA) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants With Treatment-emergent Adverse Events Following Each Dose of Soy | Dose safety will be investigated by compiling by treatment (e.g. 10 g dose, 20 g dose, 30 g dose) a list of adverse events such as frequency of headaches, nausea, vomiting. The study physician in consultation with the coordinator will review and determine safety | One week at each dose | |
Primary | 10 g Soy-related Gastrointestinal Symptoms | Subjects will complete a gastrointestinal symptoms questionnaire. The ratings are none, mild, moderate, and severe. | One week | |
Primary | 20 g Soy-related Gastrointestinal Symptoms | Subjects will complete a gastrointestinal symptoms questionnaire. The ratings are none, mild, moderate, and severe. | One week | |
Primary | 30 g Soy-related Gastrointestinal Symptoms | Subjects will complete a gastrointestinal symptoms questionnaire. The ratings are none, mild, moderate, and severe. | One week | |
Primary | 10 g Soy-related Stool Frequency | Subjects will complete the stool frequency questionnaire. Stool frequency will be rated from 0 to more than 9 over three consecutive days in each week | One week | |
Primary | 20 g Soy-related Stool Frequency | Subjects will complete the stool frequency questionnaire. Stool frequency will be rated from 0 to more than 9 over three consecutive days in each week | One week | |
Primary | 30 g Soy-related Stool Frequency | Subjects will complete the stool frequency questionnaire. Stool frequency will be rated from 0 to more than 9 over three consecutive days in each week | One week | |
Primary | 10 Soy-related Stool Consistency | Subjects will complete a stool consistency questionnaire. Stool consistency will be rated according to the Bristol Stool Scale where scores from three to five will be considered normal and 1, 2, 6, and 7 will be considered abnormal. | One week | |
Primary | 20 g Soy-related Stool Consistency | Subjects will complete a stool consistency questionnaire. Stool consistency will be rated according to the Bristol Stool Scale where scores from three to five will be considered normal and 1, 2, 6, and 7 will be considered abnormal. | One week | |
Primary | 30 g Soy-related Stool Consistency | Subjects will complete a stool consistency questionnaire. Stool consistency will be rated according to the Bristol Stool Scale where scores from three to five will be considered normal and 1, 2, 6, and 7 will be considered abnormal. | One week | |
Secondary | 10 g Soy Intake Effect on Fecal Short Chain Fatty Acids | Measurement of fecal short chain fatty acids in response to intake of soy | One week | |
Secondary | 20 g Soy Intake Effect on Fecal Short Chain Fatty Acids | Measurement of fecal short chain fatty acids in response to intake of soy | One week | |
Secondary | 30 g Soy Intake Effect on Fecal Short Chain Fatty Acids | Measurement of fecal short chain fatty acids in response to intake of soy | One week |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04485481 -
Single and Multiple Ascending Dose Study of ADX-914 in Healthy Adult Volunteers
|
Phase 1 | |
Completed |
NCT03473236 -
Phase 1A Safety Trial of Inhaled PK10571 (GB002)
|
Phase 1 | |
Not yet recruiting |
NCT03683953 -
The Treatment of Bronchopulmonary Dysplasia by Intratracheal Instillation of Mesenchymal Stem Cells
|
Phase 1 | |
Recruiting |
NCT05546567 -
NOPARK Open Label Extension Study
|
N/A | |
Recruiting |
NCT05413226 -
Effect of Different Ingestion Doses of Celastrol on Human Sperm Motility
|
N/A | |
Recruiting |
NCT05112159 -
Study of IPG1094 in Healthy Participants
|
Phase 1 | |
Completed |
NCT04689035 -
A Phase 1 Study in Healthy Volunteers to Evaluate the Safety, Tolerability and Pharmacokinetics of AVLX-144
|
Phase 1 | |
Completed |
NCT04335045 -
Phase I Study of PH100 (Ecklonia Cava Phlorotannins)
|
Phase 1 | |
Completed |
NCT05037227 -
Safety Profile Following Inactivated COVID-19 Vaccine in Healthy Adults Aged >18 Years in Indonesia
|
||
Recruiting |
NCT05517291 -
DCB Versus Primary Selective Stenting in TASC C/D Femoropopliteal Artery Disease
|
N/A | |
Enrolling by invitation |
NCT06446778 -
Haemodynamic Mechanisms and Multicentre Prospective Cohort Study of the Pipeline Flow-diverting Device for the Treatment of Intracranial Aneurysms. Evaluation of the Safety and Efficacy of the Pipeline Flow-diverting Device for the Treatment of Intracranial Aneurysms
|
||
Recruiting |
NCT04573049 -
The Effectiveness and Safety of Levosimendan in Patients With Severe Aortic Stenosis and Heart Failure Undergoing Transcatheter Aortic Valve Replacement
|
Phase 4 | |
Completed |
NCT05585463 -
Safety of Acupuncture and Intracutaneous Needles in Pediatric Cancer Patients: a Retrospective Study (ACUSAFE2021)
|
||
Completed |
NCT04188821 -
Reduction of Seroma and Improvement of QoL in Breast Reconstruction With Tissue Expander
|
N/A | |
Completed |
NCT03667430 -
Safety Evaluation of Porous Silica in Men
|
N/A | |
Completed |
NCT03141905 -
Sick-Day Protocol to Improve Outcomes in Chronic Kidney Disease
|
N/A | |
Completed |
NCT05244161 -
A Quasi-experimental Evaluation of the Malezi Program in Tanzania
|
N/A | |
Recruiting |
NCT03791372 -
Clinical Effect and Safety of Autologous Umbilical Cord Blood Transfusion in the Treatment of Cerebral Palsy
|
Phase 1 | |
Not yet recruiting |
NCT04774900 -
Standardization of Ambulance Equipment
|
||
Withdrawn |
NCT04759066 -
The HEALiX™ Intubated Patient (IP) Pilot Study
|
N/A |